Academic Journal
Προβολή σε EDS

Epstein-Barr virus receptors: classification, functional mechanisms, and pathogenic implications.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Epstein-Barr virus receptors: classification, functional mechanisms, and pathogenic implications.
Συγγραφείς: Gu H; Hunan Key Laboratory of Cancer Metabolism Changsha, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.; Xiangya School of Basic Medicine, Cancer Research Institute, Central South University, Changsha, Hunan, China.; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Changsha, Hunan, China., Yang S; Hunan Key Laboratory of Cancer Metabolism Changsha, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.; Xiangya School of Basic Medicine, Cancer Research Institute, Central South University, Changsha, Hunan, China.; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Changsha, Hunan, China., Song L; Hunan Key Laboratory of Cancer Metabolism Changsha, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.; Xiangya School of Basic Medicine, Cancer Research Institute, Central South University, Changsha, Hunan, China.; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Changsha, Hunan, China., Wang X; Hunan Key Laboratory of Cancer Metabolism Changsha, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.; Xiangya School of Basic Medicine, Cancer Research Institute, Central South University, Changsha, Hunan, China.; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Changsha, Hunan, China., Zheng X; Department of Pathology, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China., Ma J; Hunan Key Laboratory of Cancer Metabolism Changsha, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.; Xiangya School of Basic Medicine, Cancer Research Institute, Central South University, Changsha, Hunan, China.; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Changsha, Hunan, China.; Furong Laboratory, Changsha, Hunan, China.
Πηγή: Journal of virology [J Virol] 2026 Jun 23; Vol. 100 (6), pp. e0029126. Date of Electronic Publication: 2026 May 11.
Τύπος έκδοσης: Journal Article; Review
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: American Society For Microbiology Country of Publication: United States NLM ID: 0113724 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-5514 (Electronic) Linking ISSN: 0022538X NLM ISO Abbreviation: J Virol Subsets: MEDLINE
Imprint Name(s): Publication: Washington Dc : American Society For Microbiology
Original Publication: Baltimore, American Society for Microbiology.
Ιατρικοί όροι (MeSH): Herpesvirus 4, Human*/metabolism , Herpesvirus 4, Human*/physiology , Herpesvirus 4, Human*/pathogenicity , Epstein-Barr Virus Infections*/virology , Epstein-Barr Virus Infections*/metabolism , Receptors, Virus*/metabolism , Receptors, Virus*/classification , Receptors, Virus*/genetics , Receptors, Virus*/chemistry, B-Lymphocytes/virology ; B-Lymphocytes/metabolism ; Receptor, EphA2/metabolism ; Receptors, Complement 3d/metabolism ; Receptors, Complement 3d/genetics ; Epithelial Cells/virology ; Humans ; Animals
Περίληψη: Epstein-Barr virus (EBV) is a widely prevalent γ-herpesvirus that primarily infects human B cells and epithelial cells. It is closely associated with the development of various lymphomas and epithelial cancers, posing a significant threat to human life and health. The infection process of EBV relies on interactions between the virus and specific receptors on the surface of host cells, including CD21, NRP1, EphA2, and, more recently, discovered receptors such as R9AP and DSC2. Currently, no specific drugs targeting EBV have been developed, making further research on EBV receptors particularly crucial. This review summarizes the classification, structural characteristics, and molecular mechanisms of the EBV receptors identified to date and compares the differential pathways through which these receptors function in B cells and epithelial cells. Furthermore, this review discusses the potential applications of targeting EBV receptors in antiviral therapy, vaccine development, and cancer immunotherapy, while addressing the limitations of current research and future directions. The aim is to broaden the scope of future research in the field of EBV receptors and provide new perspectives for the prevention and treatment of EBV-associated diseases.
Competing Interests: The authors declare no conflict of interest.
References: Nat Microbiol. 2019 Mar;4(3):404-413. (PMID: 30664667)
Immunity. 2019 May 21;50(5):1305-1316.e6. (PMID: 30979688)
Nat Microbiol. 2025 Nov;10(11):2781-2796. (PMID: 41006833)
Eur J Immunol. 1990 Feb;20(2):409-16. (PMID: 1690137)
Lancet. 1977 Feb 12;1(8007):335-8. (PMID: 64861)
Mol Biol Cell. 2009 May;20(10):2572-81. (PMID: 19321667)
J Mol Graph Model. 2022 Jul;114:108196. (PMID: 35500362)
NPJ Vaccines. 2024 Jun 26;9(1):120. (PMID: 38926438)
Curr Opin Oncol. 2022 Sep 1;34(5):422-431. (PMID: 35900729)
Biochem Soc Trans. 2011 Dec;39(6):1583-91. (PMID: 22103491)
Nat Med. 2005 May;11(5):515-21. (PMID: 15834425)
Cell. 2022 Sep 29;185(20):3652-3670. (PMID: 36113467)
Proc Natl Acad Sci U S A. 1980 Sep;77(9):5307-11. (PMID: 6254073)
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11036-41. (PMID: 26290577)
Science. 2020 Nov 13;370(6518):856-860. (PMID: 33082293)
Cell. 2026 Jan 22;189(2):569-584.e14. (PMID: 41534530)
Mult Scler. 2011 Oct;17(10):1185-93. (PMID: 21685232)
Nat Microbiol. 2018 Feb;3(2):1-8. (PMID: 29292383)
Cell. 2026 Jan 22;189(2):345-347. (PMID: 41576916)
Nat Med. 2012 Jun;18(6):961-6. (PMID: 22635007)
Trends Microbiol. 2007 Nov;15(11):500-7. (PMID: 17988871)
Nat Microbiol. 2025 Nov;10(11):2768-2780. (PMID: 40715781)
J Exp Med. 1991 Dec 1;174(6):1299-311. (PMID: 1660522)
J Virol. 1988 Dec;62(12):4452-64. (PMID: 2460635)
Nature. 2025 Oct;646(8083):171-179. (PMID: 40770101)
N Engl J Med. 2020 Nov 12;383(20):1920-1931. (PMID: 32663912)
Br J Cancer. 2025 Nov;133(8):1085-1095. (PMID: 40783630)
Nature. 2026 May;653(8113):190-199. (PMID: 41629701)
Cell Rep. 2013 Feb 21;3(2):371-85. (PMID: 23416052)
Curr Hematol Malig Rep. 2015 Dec;10(4):456-67. (PMID: 26449716)
Cancer Sci. 2021 Nov;112(11):4799-4811. (PMID: 34449934)
Mol Vis. 2011;17:1553-8. (PMID: 21686326)
J Dermatol. 2014 Jan;41(1):29-39. (PMID: 24438142)
Cell Mol Life Sci. 2013 Jan;70(1):1-21. (PMID: 22565821)
Nat Microbiol. 2024 May;9(5):1256-1270. (PMID: 38649412)
Science. 2022 Jan 21;375(6578):296-301. (PMID: 35025605)
Microorganisms. 2025 Nov 27;13(12):. (PMID: 41471908)
J Virol. 2014 May;88(10):5559-77. (PMID: 24600013)
Nat Commun. 2015 Feb 11;6:6240. (PMID: 25670642)
J Infect Dis. 2007 Dec 15;196(12):1749-53. (PMID: 18190254)
Virulence. 2010 Sep-Oct;1(5):395-8. (PMID: 21178476)
Dev Dyn. 2011 Jun;240(6):1578-85. (PMID: 21465626)
J Immunol Res. 2022 May 26;2022:9710376. (PMID: 35664353)
J Mol Biol. 2001 May 4;308(3):501-14. (PMID: 11327783)
N Engl J Med. 1988 Mar 24;318(12):733-41. (PMID: 2831453)
Adv Immunol. 1989;46:183-219. (PMID: 2551147)
Brain. 2009 Dec;132(Pt 12):3318-28. (PMID: 19638446)
Cell Commun Adhes. 2014 Jun;21(3):129-40. (PMID: 24738885)
Semin Immunopathol. 2012 May;34(3):425-41. (PMID: 22461020)
Cancer Manag Res. 2020 Nov 09;12:11453-11462. (PMID: 33204158)
Int J Oncol. 2023 Aug;63(2):. (PMID: 37417358)
J Virol. 1990 Mar;64(3):1348-52. (PMID: 2154612)
Cell. 1987 Jul 17;50(2):203-13. (PMID: 3036369)
J Neuroimmunol. 2024 Apr 15;389:578314. (PMID: 38422689)
Sci China Life Sci. 2025 Feb;68(2):354-380. (PMID: 39505801)
J Virol. 2020 May 18;94(11):. (PMID: 32238579)
J Biol Chem. 2011 Oct 28;286(43):37368-78. (PMID: 21908615)
Microbiol Mol Biol Rev. 1999 Sep;63(3):725-34. (PMID: 10477314)
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16242-3. (PMID: 25385596)
Cell. 2026 Jan 22;189(2):603-619.e25. (PMID: 41534531)
J Virol. 2007 Aug;81(15):7825-32. (PMID: 17459936)
Nature. 2025 Aug;644(8075):205-213. (PMID: 40533557)
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9755-60. (PMID: 12119397)
J Immunother Cancer. 2021 Oct;9(10):. (PMID: 34599026)
Ann Oncol. 2002;13 Suppl 1:23-9. (PMID: 12078898)
Immunity. 2025 Feb 11;58(2):295-308.e5. (PMID: 39909035)
Neurobiol Aging. 2014 Jan;35(1):122-9. (PMID: 23916950)
J Cancer Res Clin Oncol. 2022 Jan;148(1):31-46. (PMID: 34705104)
Mol Med Rep. 2014 Nov;10(5):2358-64. (PMID: 25119898)
Chin J Cancer. 2014 Nov;33(11):545-8. (PMID: 25322867)
Proc Natl Acad Sci U S A. 1984 Jul;81(14):4510-4. (PMID: 6087328)
Sci Transl Med. 2022 May 4;14(643):eabf3685. (PMID: 35507671)
J Cell Sci. 2008 Jan 1;121(Pt 1):11-8. (PMID: 18096687)
Front Immunol. 2025 Jan 03;15:1530364. (PMID: 39830517)
Methods Enzymol. 2004;390:178-96. (PMID: 15488178)
Nat Microbiol. 2018 Feb;3(2):172-180. (PMID: 29292384)
Virology. 2008 Jan 20;370(2):430-42. (PMID: 17945327)
Lancet. 1980 Mar 8;1(8167):536-7. (PMID: 6102249)
J Hepatol. 2025 Jan;82(1):37-50. (PMID: 38960374)
J Biol Chem. 2007 Dec 14;282(50):36614-25. (PMID: 17925391)
Sci Transl Med. 2025 Nov 12;17(824):eady0210. (PMID: 41223250)
Virology. 2007 Mar 15;359(2):382-96. (PMID: 17081581)
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20464-9. (PMID: 19920174)
Oncogene. 2021 Apr;40(14):2483-2495. (PMID: 33686241)
mBio. 2015 Dec 01;6(6):e01844-15. (PMID: 26628726)
J Virol. 1987 May;61(5):1416-20. (PMID: 3033269)
J Pathol. 2010 Jul;221(3):275-84. (PMID: 20527021)
Chin J Cancer. 2014 Dec;33(12):609-19. (PMID: 25418195)
Cell Host Microbe. 2024 Jun 12;32(6):980-995.e9. (PMID: 38729153)
Nat Rev Neurol. 2023 Mar;19(3):160-171. (PMID: 36759741)
Nat Rev Immunol. 2003 Oct;3(10):801-12. (PMID: 14523386)
Ann Neurol. 2002 Nov;52(5):543-8. (PMID: 12402250)
Mol Cells. 2016 Apr 30;39(4):286-91. (PMID: 27094060)
Nat Rev Microbiol. 2021 Feb;19(2):110-121. (PMID: 33087881)
Nature. 2022 Mar;603(7900):321-327. (PMID: 35073561)
Clin Cancer Res. 2014 Oct 1;20(19):5075-84. (PMID: 25117294)
Genes (Basel). 2013 Jul 01;4(3):334-57. (PMID: 24705208)
Nat Commun. 2020 Nov 24;11(1):5964. (PMID: 33235207)
Adv Sci (Weinh). 2023 Dec;10(35):e2302116. (PMID: 37890462)
Cell Rep. 2025 Jan 28;44(1):115168. (PMID: 39792550)
Mol Cell. 2002 Feb;9(2):375-85. (PMID: 11864610)
HIV Med. 2007 Jul;8(5):306-11. (PMID: 17561877)
NPJ Vaccines. 2022 Dec 9;7(1):159. (PMID: 36494369)
Grant Information: 82460464 National Natural Science Foundation of China; 82472701 National Natural Science Foundation of China; 2026JJ30148 Hunan Natural Sciences Foundation
Contributed Indexing: Keywords: CD21; DSC2; EBV receptors; EphA2; Epstein-Barr virus; R9AP
Substance Nomenclature: 0 (Receptors, Virus)
EC 2.7.10.1 (Receptor, EphA2)
0 (Receptors, Complement 3d)
0 (EPHA2 protein, human)
Entry Date(s): Date Created: 20260511 Date Completed: 20260628 Latest Revision: 20260813
Update Code: 20260813
PubMed Central ID: PMC13288826
DOI: 10.1128/jvi.00291-26
PMID: 42112902
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1098-5514
DOI:10.1128/jvi.00291-26